Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

• Late Breaking Abstract and Oral Presentation on ATH434-202 Interim Phase 2 Data - - Oral Presentation on ATH434-201 Phase 2 Baseline Characteristics - MELBOURNE, Australia and SAN FRANCISCO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presentations will be presented at the Internationa ...